Centanamycin

Drug Profile

Centanamycin

Alternative Names: AS-1-145; D716970; ML-970; NSC 716970

Latest Information Update: 21 Oct 2013

Price : $50

At a glance

  • Originator Hope College; Spirogen
  • Developer Hope College; National Cancer Institute (USA); Spirogen
  • Class Amides; Antimalarials; Cytostatic antibiotics; Indoles; Naphthalenes
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Malaria

Most Recent Events

  • 15 Oct 2013 Spirogen has been acquired by MedImmune
  • 01 Mar 2011 Preclinical development is ongoing in USA
  • 22 Apr 2009 Preclinical trials in Malaria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top